Crinetics Pharmaceuticals (NASDAQ:CRNX) Given “Overweight” Rating at Cantor Fitzgerald
Cantor Fitzgerald reissued their overweight rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a report published on Friday morning, Benzinga reports. They currently have a $50.00 price objective on the stock. Several other research firms have also commented on CRNX. Morgan Stanley initiated coverage on shares of Crinetics Pharmaceuticals in a research […]
More Stories
Tilray (NASDAQ:TLRY) Shares Up 8% – What’s Next?
Tilray Inc (NASDAQ:TLRY – Get Free Report) rose 8% on Thursday . The company traded as high as $1.45 and...
Cacti Asset Management LLC Lowers Stock Position in U.S. Bancorp (NYSE:USB)
Cacti Asset Management LLC reduced its position in shares of U.S. Bancorp (NYSE:USB – Free Report) by 4.7% during the...
BancFirst Trust & Investment Management Purchases 249 Shares of AbbVie Inc. (NYSE:ABBV)
BancFirst Trust & Investment Management lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 7.3% during...
D-Wave Quantum (NYSE:QBTS) Shares Up 1.9% – Should You Buy?
D-Wave Quantum Inc. (NYSE:QBTS – Get Free Report)’s stock price traded up 1.9% during trading on Thursday . The company...
Eos Energy Enterprises Sees Unusually High Options Volume (NASDAQ:EOSE)
Eos Energy Enterprises, Inc. (NASDAQ:EOSE – Get Free Report) was the target of unusually large options trading on Thursday. Investors...
NVIDIA (NASDAQ:NVDA) Shares Up 2.6% – Here’s What Happened
Shares of NVIDIA Co. (NASDAQ:NVDA – Get Free Report) traded up 2.6% during trading on Thursday . The company traded...